These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 15262845

  • 1. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.
    Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O'Driscoll G, Macdonald P, Esmore D, Muller D, Faddy S.
    Circulation; 2004 Oct 26; 110(17):2694-700. PubMed ID: 15262845
    [Abstract] [Full Text] [Related]

  • 2. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
    Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P, RAD B253 Study Group.
    N Engl J Med; 2003 Aug 28; 349(9):847-58. PubMed ID: 12944570
    [Abstract] [Full Text] [Related]

  • 3. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
    Viganò M, Tuzcu M, Benza R, Boissonnat P, Haverich A, Hill J, Laufer G, Love R, Parameshwar J, Pulpón LA, Renlund D, Abeywickrama K, Cretin N, Starling RC, Eisen HJ, RAD B253 Study Group.
    J Heart Lung Transplant; 2007 Jun 28; 26(6):584-92. PubMed ID: 17543781
    [Abstract] [Full Text] [Related]

  • 4. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
    Eisen H.
    Nephrol Dial Transplant; 2006 Jul 28; 21 Suppl 3():iii9-13. PubMed ID: 16815858
    [Abstract] [Full Text] [Related]

  • 5. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination.
    Machado PG, Felipe CR, Hanzawa NM, Park SI, Garcia R, Alfieri F, Franco M, Silva HT, Medina-Pestana JO.
    Clin Transplant; 2004 Feb 28; 18(1):28-38. PubMed ID: 15108768
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.
    Kahan BD.
    Lancet; 2000 Jul 15; 356(9225):194-202. PubMed ID: 10963197
    [Abstract] [Full Text] [Related]

  • 7. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
    Zucker MJ, Baran DA, Arroyo LH, Goldstein DJ, Neacy C, Mele L, Weinberg AD, Prendergast TW, Ribner HS.
    Transplant Proc; 2005 Jun 15; 37(5):2231-9. PubMed ID: 15964386
    [Abstract] [Full Text] [Related]

  • 8. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K.
    Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239
    [Abstract] [Full Text] [Related]

  • 9. Use of rapamycin slows progression of cardiac transplantation vasculopathy.
    Mancini D, Pinney S, Burkhoff D, LaManca J, Itescu S, Burke E, Edwards N, Oz M, Marks AR.
    Circulation; 2003 Jul 08; 108(1):48-53. PubMed ID: 12742978
    [Abstract] [Full Text] [Related]

  • 10. Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients.
    Costanzo MR, Koch DM, Fisher SG, Heroux AL, Kao WG, Johnson MR.
    J Heart Lung Transplant; 1997 Feb 08; 16(2):169-78. PubMed ID: 9059928
    [Abstract] [Full Text] [Related]

  • 11. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 08; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 12. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial.
    Valantine H.
    J Heart Lung Transplant; 2005 Apr 08; 24(4 Suppl):S191-5; discussion S210-1. PubMed ID: 15774321
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
    Ettenger RB, Grimm EM.
    Am J Kidney Dis; 2001 Oct 08; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
    [Abstract] [Full Text] [Related]

  • 14. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection.
    Tsai MK, Chueh SC, Hu RH, Lee PH.
    J Formos Med Assoc; 2003 Feb 08; 102(2):91-6. PubMed ID: 12709737
    [Abstract] [Full Text] [Related]

  • 15. A single-center open label randomized trial of the safety and efficacy of the use of sirolimus versus azathioprine in one-haplotype living related kidney transplant recipients-preliminary results.
    Machado PG, Garcia C, Felipe CR, Garcia R, Franco M, Delcelo R, Silva HT, Medina JO.
    Transplant Proc; 2001 Feb 08; 33(1-2):1074-5. PubMed ID: 11267196
    [No Abstract] [Full Text] [Related]

  • 16. The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study.
    Mühlbacher F, Neumayer HH, del Castillo D, Stefoni S, Zygmunt AJ, Budde K, European Rapamune Cyclosporine Minimization Study Group.
    Transpl Int; 2014 Feb 08; 27(2):176-86. PubMed ID: 24266855
    [Abstract] [Full Text] [Related]

  • 17. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
    Arora S, Andreassen AK, Karason K, Gustafsson F, Eiskjær H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Dellgren G, Ueland T, Aukrust P, Gullestad L, SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators.
    Circ Heart Fail; 2018 Sep 08; 11(9):e004050. PubMed ID: 30354362
    [Abstract] [Full Text] [Related]

  • 18. Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious.
    Meiser B, Kaczmarek I, Mueller M, Groetzner J, Weis M, Knez A, Stempfle HU, Klauss V, Schmoeckel M, Reichart B, Ueberfuhr P.
    J Heart Lung Transplant; 2007 Jun 08; 26(6):598-603. PubMed ID: 17543783
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience.
    Lobach NE, Pollock-Barziv SM, West LJ, Dipchand AI.
    J Heart Lung Transplant; 2005 Feb 08; 24(2):184-9. PubMed ID: 15701435
    [Abstract] [Full Text] [Related]

  • 20. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.